| 摘要: |
| ［摘要］ 目的 探析依折麦布联合瑞舒伐他汀（可定）对低密度脂蛋白胆固醇未达标的急性冠脉综合征患者胆固醇代谢的影响。方法 采用随机数字表法将2016-02～2017-02收治的210例低密度脂蛋白胆固醇未达标的急性冠脉综合征患者分为对照组（瑞舒伐他汀治疗）及观察组（依折麦布联合瑞舒伐他汀治疗）各105例持续治疗12周，对两组胆固醇代谢影响效果进行比较。结果 观察组不良反应总发生率为6.67%，与对照组4.76%比较，差异无统计学意义（P>0.05）。治疗前两组胆固醇代谢指标无明显差异，治疗后观察组各指标数值优于对照组，差异有统计学意义（P<0.05）。结论 在低密度脂蛋白胆固醇未达标的急性冠脉综合征患者治疗中依折麦布联合瑞舒伐他汀改善胆固醇代谢效果更佳，可作为优选方案推广使用。 |
| 关键词: 依折麦布 瑞舒伐他汀 低密度脂蛋白胆固醇 急性冠脉综合征 |
| DOI：10.3969/j.issn.1674-3806.2018.03.08 |
| 分类号:R 541 |
| 基金项目: |
|
| Effects of ezetimibe and rosuvastatin on cholesterol metabolism in patients with acute coronary syndromes with low-density lipoprotein cholesterol |
|
BU Rong-sheng, DU Xin-qing, WU Chun-chun
|
|
The Second Department of Cardiology, the Second Affiliated Hospital of Fujian Medical University, Fujian 362000, China
|
| Abstract: |
| ［Abstract］ Objective To investigate the effect of rituximab combined with rosuvastatin on cholesterol metabolism in the patients with acute coronary syndromes and low-density lipoprotein cholesterol.Methods A total of 210 patients with acute coronary syndromes and low-density lipoprotein cholesterol were divided into the control group(treated with rosuvastatin) and the observation group(receiving ezetimibe combined with rosuvastatin) from February 2016 to February 2017 by the random number table method, with 105 cases in each group. The cholesterol metabolism effects were compared between the two groups after a continuous treatment for 12 weeks.Results There was no significant difference in the total incidence of adverse reactions between the observation group(6.67%) and the control group(4.76%). There were no significant differences in the indexes of cholesterol metabolism between the two groups before treatment(P>0.05). After treatment, the improvement of the indexes of cholesterol metabolism in the observation group was better than that in the control group(P<0.05).Conclusion Ezetimibe combined with rosuvastatin improves cholesterol metabolism better and may be used as a preferred regimen in the patients with acute coronary syndromes and low-density lipoprotein cholesterol. |
| Key words: Ezetimibe Rosuvastatin Low-density lipoprotein cholesterol Acute coronary syndrome |
